STOCK TITAN
  1. Home
  2. News
  3. AKLI

Akili Inc - AKLI STOCK NEWS

Welcome to our dedicated news page for Akili (Ticker: AKLI), a resource for investors and traders seeking the latest updates and insights on Akili.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akili's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akili's position in the market.

News
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Akili, Inc. (Nasdaq: AKLI) reports significant revenue growth in FY 2023, with total revenues of $1.7M, a 420% increase over FY 2022. The company's partner, Shionogi, releases positive Phase 3 trial results for SDT-001, submitting it for marketing approval in Japan. Akili lowers FY 2024 non-GAAP total operating expense guidance and reaffirms gross margins guidance. The company ends FY 2023 with $75.2 million in cash and cash equivalents, ensuring cash runway into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
earnings
-
News
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Rhea-AI Summary
PureTech Health's Japanese partner, Shionogi & Co. Ltd, submits Akili's digital therapeutic SDT-001 for marketing approval in Japan, a localized version of AKL-T01. The Phase 3 clinical trial results show significant improvements in pediatric ADHD patients. Positive outcomes pave the way for potential nationwide marketing approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
clinical trial
-
News
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
Rhea-AI Summary
Akili, Inc. (Nasdaq: AKLI) and its Japanese partner, Shionogi & Co. Ltd, have submitted SDT-001 for marketing approval in Japan. SDT-001 is the Japanese version of Akili's AKL-T01, known as EndeavorRx® in the US, the world's first prescription digital therapeutic for pediatric ADHD. The Phase 3 trial in Japan showed significant improvements in ADHD symptoms with no safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
103.6%
Tags
clinical trial
News
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
Rhea-AI Summary
Akili, Inc. (Nasdaq: AKLI) announced plans to disclose Q4/FY 2023 financial results on February 29, 2024. CEO Matthew Franklin will participate in a fireside chat at TD Cowen’s 44th Annual Healthcare Conference on March 4, 2024. The company appointed John Spinale to the Board of Directors and Audit Committee. Akili also provided updates on the April 17, 2024 Annual Meeting and efforts to regain compliance with Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
earnings
-
News
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
Rhea-AI Summary
Akili, Inc. (Nasdaq: AKLI) has received FDA authorization to expand the label for EndeavorRx® from 8 to 12 year-old patients with primarily inattentive or combined-type ADHD to include older children aged 13 - 17. This expanded age range is expected to more than double the number of pediatric patients with ADHD eligible for EndeavorRx. The clinical study involved 162 adolescents with a verified diagnosis of inattentive or combined-type ADHD who all received EndeavorRx for 4 weeks and demonstrated significant improvements in attentional control. Additionally, 27.1% of participants in the study demonstrated at least a 30% reduction in total scores on the ADHD-RS, and statistically significant improvements were observed for parent and child ratings of attention improvement, as well as parent ratings of function across several domains.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
none
-
News
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Akili, Inc. (Nasdaq: AKLI) reports third quarter total revenues of $702 thousand, representing more than 5x growth over the second quarter of 2023. The company has filed EndeavorOTC with FDA as an over-the-counter treatment for adults with ADHD, emphasizing a strategic shift to a non-prescription business model. In the third quarter of 2023, Akili saw 176,559 first-time app downloads, 7,535 active subscribers, and $553 thousand in revenues. The company's cash position as of September 30, 2023, was $86.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
earnings
News
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
Rhea-AI Summary
Akili, Inc. to host conference call and webcast to review Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
conferences earnings
-
News
PureTech to Present at Two Upcoming Investor Conferences
Rhea-AI Summary
PureTech Health announces third quarter progress and upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
-
News
Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds
Rhea-AI Summary
Akili releases study on the impact of ADHD on the U.S. workforce
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
News
Akili Announces Leadership Transition
Rhea-AI Summary
Akili, Inc. announces leadership transition and shift to non-prescription business model
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
management
Stock AKLI logo
Akili Inc

Nasdaq:AKLI

AKLI Rankings

#5150 Ranked by Market Cap
#5335 Ranked by Stock Gains
N/A Ranked by Dividends

AKLI Stock Data

17.67M
26.11M
23.26%
54.19%
0.16%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Boston